Gyre Therapeutics Inc. (GYRE)
7.69
0.17 (2.26%)
At close: Apr 14, 2025, 3:59 PM
7.72
0.39%
After-hours: Apr 14, 2025, 04:05 PM EDT
2.26% (1D)
| Bid | 6.58 |
| Market Cap | 659.97M |
| Revenue (ttm) | 105.76M |
| Net Income (ttm) | 28.54M |
| EPS (ttm) | 0.05 |
| PE Ratio (ttm) | 153.8 |
| Forward PE | 25.52 |
| Analyst | n/a |
| Ask | 8.8 |
| Volume | 106,318 |
| Avg. Volume (20D) | 139,829 |
| Open | 7.56 |
| Previous Close | 7.52 |
| Day's Range | 7.38 - 7.72 |
| 52-Week Range | 6.11 - 19.00 |
| Beta | 2.41 |
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney dise...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 579
Stock Exchange NASDAQ
Ticker Symbol GYRE
Website https://www.gyretx.com
3 weeks ago
-30.21%
Gyre Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
5 months ago
-9.56%
Gyre Therapeutics shares are trading lower after the company reported a year-over-year decline in Q3 financial results.
